RESUMEN
BACKGROUND: In spite of substantial declines in both incidence and mortality rates in the past 50 years, cervical cancer remains one of the leading causes of cancer associated mortality among women globally. We performed this meta-analysis to explore the role of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphism with susceptibility to cervical carcinoma. METHODS: The search databases include PubMed, SciELO, MedRxiv, Web of Science, Scopus, Cochrane Library, China National Knowledge Infrastructure, and China Biology Medicine disc up to 30 June 2021. The language is limited to English and Chinese. The comparison between the polymorphisms and cervical cancer was assessed using pooled odds ratio (OR) and 95% confidence interval (CI). The data are statistically analyzed by Comprehensive Meta-Analysis (CMA) 2.0 software. RESULTS: A total of 59 studies including seven studies with 1,112 cases and 1,233 controls on XRCC3 rs861539, 14 studies with 2,694 cases and 3349 controls MTHFR rs1801133, four studies with 1,121 cases and 1,109 controls on IL-12B rs3212227, seven studies with 1,452 cases and 2,186 controls on IL-6 rs1800795, 20 studies with 4,781 cases and 4909 controls on TNF-α rs1800629, and seven studies with 1743 cases and 2292 controls on TLR9 rs352140 were included. There was a significant association between XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 polymorphisms and an increased risk of cervical carcinoma in overall population. However, the MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms were not associated. CONCLUSION: The pooled analysis showed that XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 were associated with cervical carcinoma susceptibility, but not MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms.
Asunto(s)
Carcinoma/genética , Predisposición Genética a la Enfermedad/genética , Polimorfismo Genético/genética , Neoplasias del Cuello Uterino/genética , Estudios de Casos y Controles , Proteínas de Unión al ADN/genética , Femenino , Humanos , Subunidad p40 de la Interleucina-12/genética , Interleucina-6/genética , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Oportunidad Relativa , Factores de Riesgo , Receptor Toll-Like 9/genética , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
OBJECTIVE: The effects of the MTHFR 677Câ¯>â¯T polymorphism on the intrauterine growth restriction (IUGR) and placental abruption risk have been evaluated in some studies. However, those studies results were conflicting and ambiguous. Therefore, we carried out the current meta-analysis to evaluate the association of MTHFR 677Câ¯>â¯T polymorphism with risk of IUGR and placental abruption from all eligible studies. METHODS: An electronic search of the PubMed, Embase, Scopus and CNKI databases was performed up to February 25, 2020. RESULTS: A total of 25 case-control studies including eight studies with 687 cases and 2336 controls for IUGR and 17 studies with 1574 cases and 5758 controls for placental abruption were selected. The analysis results indicated that MTHFR 677Câ¯>â¯T polymorphism was associated with an increased risk of IUGR and placental abruption in global population. When stratified by ethnicity a significant association between the MTHFR 677Câ¯>â¯T polymorphism and IUGR risk was found in Caucasians and Africans. However, there was no a significant association between the MTHFR 677Câ¯>â¯T polymorphism and placental abruption risk by ethnicity. CONCLUSIONS: Our pooled data indicated that the MTHFR 677Câ¯>â¯T polymorphism might play a role in development of IUGR and placental abruption.